Making the Case for Valeant Pharmaceuticals Intl Inc.: Why it’s Not Worth it Yet

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock has been in shambles in 2016, plummeting more than 83%, but there is reason to be optimistic about the stock’s potential in the long term.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock has been in shambles in 2016, plummeting more than 83%, but there is reason to be optimistic about the stock’s potential in the long term.

The pharmaceutical giant has experienced several setbacks over the last 11 months. Glaucoma drug latanoprostene bunod failed to garner approval from the Food and Drug Administration (FDA) over the summer due to problems at the facility it is manufactured. More recently, psoriasis drug brodalumab’s release was also pushed back.

Valeant’s glaucoma medication could make a major splash if its February 2017 launch comes to fruition, as there is a growing demand for glaucoma drugs that will rise steadily over the next seven years. Following a decline in the industry from 2012 to 2015, the glaucoma market has bounced back, and it was worth $5.7 billion in 2015. The market is expected to be worth $7.6 billion by 2024.

Murray Fingeret, OD, chief of the optometry at the Department of Veterans Administration New York Harbor Healthcare System in New York City, tested latanoprostene bunod and backed it as an effective remedy for glaucoma.

Additionally, Valeant’s auto-immune medication brodalumab was rejected by the FDA due to concerns regarding how the product is labelled rather than the efficacy of the product itself. Six of 6,000 patients who used the drug committed suicide, marking a 300% increase over the average of two suicides per 6,000.

Naturally, there could be other factors contributing to these statistics, and Valeant has three months to hash out the details of the product before receiving FDA approval. Experts have also backed the medication as an effective treatment for the skin condition, psoriasis.

Nevertheless, investors have good reason to be cautious in committing to the stock in the short term as third-quarter earnings were 18 cents per share below estimate, while revenue fell 11% year over year. Additionally, the company took a goodwill impairment charge of $1.05 billion.

On top of these figures, Valeant seems like it will be gloomy in 2017 as numerous company medications are losing exclusivity, including its heavy-metal toxicity treatment Syprine, heart drug Nitropress, hepatitis C medication Virazole, and blood-pressure treatment Isuprel. Irritable-bowel-syndrome medication Xifaxan was named as the company’s “billion-dollar product of 2016” by its former boss, and it has been a total fiasco.

Additionally, Valeant is $30 billion in debt and it needs a controller, a head of quality, and solid advice to give the company the necessary boost it needs.

Despite it all, CEO Joe Papa seems optimistic; the company expects to have its debt re-cued to $5 billion by 2018, while prices for skin products are rising by an average of 40%. Between the potential of brodalumab and latanoprostene bunod, Valeant may be making the first steps towards its turnaround efforts. However, the decline of its core products will continue to push down the stock through the rest of the year and much of 2017.

The company is currently in the process of selling some assets to help reduce its debt, including its Salix unit, which may be acquired by Japanese pharma Takeda for $10 billion ($5 billion lower than what Valeant shelled out for it in 2015).

Valeant shares are down 1.8% at Tuesday’s market close with the stock trading at $23.05. Valeant has a market cap of $8 billion.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karl Utermohlen has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Tractor spraying a field of wheat
Investing

Is Nutrien Stock a Buy for its 4.7% Dividend Yield?

Nutrien (TSX:NTR) is a well-known defensive commodities play. But is this stock worth buying for its dividend yield alone?

Read more »

Happy shoppers look at a cellphone.
Tech Stocks

So You Own Shopify Stock: Is it Still a Good Investment?

Shopify (TSX:SHOP) stock has had a run, but there's still room to the upside.

Read more »

Paper Canadian currency of various denominations
Investing

The Best Stocks to Invest $2,000 in Right Now

Do you have some extra cash to spare? Here are three Canadian stocks to add to your watch list today.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, November 22

Continued gains in gold, oil, and natural gas prices could give the commodity-focused TSX benchmark a boost at the opening…

Read more »

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Is CNR Stock a Buy, Sell, or Hold for 2025?

Can CNR stock continue its long-term outperformance into 2025 and beyond? Let's explore whether now is a good time to…

Read more »

engineer at wind farm
Energy Stocks

Invest $20,000 in This Dividend Stock for $100 in Monthly Passive Income

This dividend stock has it all – a strong outlook, monthly income, and even more to consider buying today.

Read more »

Hourglass and stock price chart
Stock Market

It’s Not Too Late: Invest in These TSX Growth Stocks Now

Solid fundamentals of these top TSX growth stocks could help them maintain strong upward momentum in the years to come.

Read more »

coins jump into piggy bank
Dividend Stocks

The Smartest Dividend Stocks to Buy With $500 Right Now

These top dividend stocks both offer attractive yields and trade off their highs, making them two of the best to…

Read more »